Tobacco Harm Reduction
With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. Our methods are regularly applied in exposure and nicotine PK studies, supporting regulatory product submissions especially in the US under FDA CTP's PMTA and MRTPA.
We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements.
At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.
